Open Orphan #ORPH – £3m COVID-19 challenge virus manufacturing contract for hVIVO based on new COVID-19 variants May 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus. The contract is worth £3 million and under this agreement hVIVO will develop a new SARS-CoV-2…

Continue reading